CD8A and neoplasm: Analysis of the tumor immune infiltrate showed that DMXAA monotherapy up-regulated production of anti-tumor cytokines (i.e., IFNγ, Granzyme B, and TNFα) in both CD8+ and CD4+ T cells, which was further enhanced by combining with olaparib therapy (Fig. 5b, c).